Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76:771–80.

Article  CAS  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen CHenry L. The global epidemiology of nonalcoholic fatty Liver Disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47.

Article  PubMed  Google Scholar 

Targher G, Tilg HByrne CD. Non-alcoholic fatty Liver Disease: a multisystem Disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6:578–88.

Article  PubMed  Google Scholar 

Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, et al. Non-alcoholic fatty Liver Disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903–13.

Article  PubMed  Google Scholar 

Simon TG, Roelstraete B, Hagström H, Sundström JLudvigsson JF. Non-alcoholic fatty Liver Disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867–75.

Article  PubMed  Google Scholar 

Golabi P, Paik JM, Harring M, Younossi E, Kabbara KYounossi ZM. Prevalence of high and moderate risk nonalcoholic fatty Liver Disease among adults in the United States, 1999–2016. Clin Gastroenterol Hepatol. 2022;20:2838–47.

Article  CAS  PubMed  Google Scholar 

Rinella MESanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196–205.

Article  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of Cardiovascular Disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–69.

Article  PubMed  Google Scholar 

Carr SS, Hooper AJ, Sullivan DRBurnett JR. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic Cardiovascular Disease risk assessment. Pathology. 2019;51:148–54.

Article  CAS  PubMed  Google Scholar 

Wadström BN, Wulff AB, Pedersen KM, Jensen GBNordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery Disease, Myocardial Infarction, and ischaemic Stroke: a cohort-based study. Eur Heart J. 2022;43:3258–69.

Article  PubMed  Google Scholar 

Huang H, Guo Y, Liu Z, Zeng Y, Chen YXu C. Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty Liver Disease. J Clin Endocrinol Metab. 2022;107:e3295–303.

Article  PubMed  Google Scholar 

Huh JH, Roh E, Lee SJ, Ihm SH, Han KDKang JG. Remnant cholesterol is an Independent predictor of type 2 Diabetes: a Nationwide Population-based Cohort Study. Diabetes Care. 2022;46:305–12.

Article  Google Scholar 

Zou Y, Kuang M, Zhong YJiang C. Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population. Sci Rep. 2023;13:5957.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang H, Xie J, Zeng Y, Liu Z, Miao M. Xu LXu C. Remnant cholesterol independently predicts the development of nonalcoholic fatty Liver Disease. J Clin Endocrinol Metab. 2023.

Miao YTao H. Association between remnant lipoprotein cholesterol levels and risk of non-alcoholic fatty Liver Disease in non-obese populations: a Chinese longitudinal prospective cohort study. BMJ Open. 2023;13:e069440.

Article  Google Scholar 

Chin J, Mori TA, Adams LA, Beilin LJ, Huang R-C, Olynyk JKAyonrinde OT. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty Liver Disease in adolescents. JHEP Rep. 2020;2:100150.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, Meng X, et al. Severity of nonalcoholic fatty Liver Disease and risk of future ischemic Stroke events. Stroke. 2021;52:103–10.

Article  CAS  PubMed  Google Scholar 

Huang H, Wang Q, Shi X, Chen Y, Shen C, Zhang JXu C. Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and nonalcoholic fatty Liver Disease: a cross-sectional study. Mediators Inflamm. 2021;2021:6642246.

Article  PubMed  PubMed Central  Google Scholar 

Guo Y, Huang H, Chen Y, Shen CXu C. Association between circulating cystatin C and hyperuricemia: a cross-sectional study. Clin Rheumatol. 2022;41:2143–51.

Article  PubMed  Google Scholar 

Coleman SRM, Gaalema DE, Nighbor TD, Kurti AA. Bunn JYHiggins ST. Current cigarette Smoking among U.S. college graduates. Prev Med. 2019;128:105853.

Article  PubMed  PubMed Central  Google Scholar 

Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima JAC et al. Remnant cholesterol predicts Cardiovascular Disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, et al. 2016 ESC/EAS guidelines for the management of Dyslipidaemias. Eur Heart J. 2016;37:2999–3058.

Article  PubMed  Google Scholar 

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.

Article  PubMed  Google Scholar 

Bakris G, Ali WParati G. ACC/AHA Versus ESC/ESH on Hypertension guidelines: JACC Guideline comparison. J Am Coll Cardiol. 2019;73:3018–26.

Article  PubMed  Google Scholar 

2. Classification and diagnosis of Diabetes: standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43:14–S31.

Article  Google Scholar 

Fan JG, Wei LZhuang H. Guidelines of prevention and treatment of nonalcoholic fatty Liver Disease (2018, China). J Dig Dis. 2019;20:163–73.

Article  PubMed  Google Scholar 

Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty Liver Disease. Gastroenterology. 2017;152:598–607.

Article  PubMed  Google Scholar 

Stürzebecher PE. Katzmann JLLaufs U. What is ‘remnant cholesterol’? Eur Heart J. 2023;44:1446–8.

Article  PubMed  Google Scholar 

Liu HH, Li S, Cao YX, Guo YL, Zhu CG, Wu NQLi JJ. Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis. 2021;330:29–35.

Article  CAS  PubMed  Google Scholar 

Wadström BN, Pedersen KM, Wulff ABNordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023;44:1432–45.

Article  PubMed  Google Scholar 

Wu Z, Yu S, Zhu Q, Li Z, Zhang H, Kang X, Xu Z, et al. Association of baseline and cumulative remnant cholesterol with incidence of diabetic Nephropathy: a longitudinal cohort study. Diabetes Res Clin Pract. 2022;191:110079.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Zhang Q, Li H, Zhou G, Shi P, Zhang X, Guan L, et al. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty Liver Disease. Front Endocrinol (Lausanne). 2023;14:1098078.

Article  PubMed  Google Scholar 

Chen J, Su Y, Su XLuo F. Remnant cholesterol has a non-linear association with non-alcoholic fatty Liver Disease. Diabetes Res Clin Prac. 2023;201:110733.

Article  CAS  Google Scholar 

Cao Y-X, Zhang H-W, Jin J-L, Liu H-H, Zhang Y, Gao Y, Guo Y-L, et al. The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with Diabetes and pre-diabetes. Cardiovasc Diabetol. 2020;19:104.

Article  CAS  PubMed  PubMed Central  Google Scholar